With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
In the UK a man's average life time risk of developing prostate cancer is one in 13. That translates into 21,000 diagnoses each year, and the disease will kill 10,000 of these men. Yet a number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback